Abstract 60 Table 2

Table comparing the TTR seen in our AF cohort and that of published literature

No of patients on warfarinF/U timeTTRCompared with our cohort Chi Sq with yates correction p value <0.05 were considered significant
Dabigatran602224 months0.0124*
Rivaroxaban713323 months0.0001*
Apixaban908122 months0.0038*
Edoxaban703634 months0.0209*
- Whole study1839112 months0.9490
- AF cohort only1177012 months0.9945
  • * indicates a statistically significant difference